Treatment strategies for indolent lymphomas
| Advanced-stage disease |
| Watchful waiting |
| Alkylating agents |
| Purine analogs |
| Combination chemotherapy |
| Monoclonal antibodies |
| Unconjugated |
| Conjugated radioimmunoconjugates and immunotoxins |
| Chemotherapy + monoclonal antibodies (chemoimmunotherapy) |
| High-dose chemotherapy + autologous/allogeneic stem cell transplantation |
| Reduced intensity conditioning allogeneic stem cell transplantation |
| Palliative radiotherapy |
| Localized disease |
| Radiotherapy |
| Watchful waiting |
| Advanced-stage disease |
| Watchful waiting |
| Alkylating agents |
| Purine analogs |
| Combination chemotherapy |
| Monoclonal antibodies |
| Unconjugated |
| Conjugated radioimmunoconjugates and immunotoxins |
| Chemotherapy + monoclonal antibodies (chemoimmunotherapy) |
| High-dose chemotherapy + autologous/allogeneic stem cell transplantation |
| Reduced intensity conditioning allogeneic stem cell transplantation |
| Palliative radiotherapy |
| Localized disease |
| Radiotherapy |
| Watchful waiting |